| Year |
Citation |
Score |
| 2020 |
Venkatesh J, Rishi AK, Reddy KB. Novel strategies to target chemoresistant triple-negative breast cancer. Genes & Cancer. 11: 95-105. PMID 33488948 DOI: 10.18632/genesandcancer.204 |
0.452 |
|
| 2017 |
Yin S, Cheryan VT, Xu L, Rishi AK, Reddy KB. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. Plos One. 12: e0183578. PMID 28817737 DOI: 10.1371/Journal.Pone.0183578 |
0.556 |
|
| 2015 |
Muthu M, Somagoni J, Cheriyan VT, Munie S, Levi E, Ashour AE, Yassin AE, Alafeefy AM, Sochacki P, Polin LA, Reddy KB, Larsen SD, Singh M, Rishi AK. Identification and Testing of Novel CARP-1 Functional Mimetic Compounds as Inhibitors of Non-Small Cell Lung and Triple Negative Breast Cancers. Journal of Biomedical Nanotechnology. 11: 1608-27. PMID 26485930 DOI: 10.1166/Jbn.2015.2099 |
0.558 |
|
| 2015 |
Ahmad A, Ginnebaugh KR, Yin S, Bollig-Fischer A, Reddy KB, Sarkar FH. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. Bmc Cancer. 15: 540. PMID 26206152 DOI: 10.1186/S12885-015-1561-X |
0.488 |
|
| 2015 |
Yin S, Rishi AK, Reddy KB. Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment. Oncology Reports. 33: 1475-80. PMID 25592673 DOI: 10.3892/Or.2015.3721 |
0.557 |
|
| 2015 |
Yin S, Cheriyan VT, Rishi AK, Reddy KB. Abstract 2225: c-Myc and Frizzled 8 play a major role in the regulation of cancer stem cells and drug resistance in triple-negative breast cancer Cancer Research. 75: 2225-2225. DOI: 10.1158/1538-7445.Am2015-2225 |
0.544 |
|
| 2013 |
Yin S, Xu L, Bonfil RD, Banerjee S, Sarkar FH, Sethi S, Reddy KB. Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Molecular Cancer Therapeutics. 12: 491-8. PMID 23445611 DOI: 10.1158/1535-7163.Mct-12-1090 |
0.567 |
|
| 2013 |
Reddy KB, Yin S, Daniel RB, Banerjee S, Sarkar F, Sethi S. Abstract 241: Tumor initiating cells and FZD8 play a major role in drugresistance and tumor progression in triple negative breast cancer. Cancer Research. 73: 241-241. DOI: 10.1158/1538-7445.Am2013-241 |
0.547 |
|
| 2012 |
Wong C, Wang X, Smith D, Reddy K, Chen S. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Breast Cancer Research and Treatment. 134: 671-81. PMID 22706627 DOI: 10.1007/S10549-012-2105-6 |
0.473 |
|
| 2012 |
Ahmad A, Reddy KB, Sarkar FH. Abstract A1: Functional significance of miR-10b in tamoxifen resistance of breast cancer cells Clinical Cancer Research. 18: A1-A1. DOI: 10.1158/1078-0432.Mechres-A1 |
0.401 |
|
| 2011 |
Reddy KB. Triple-negative breast cancers: an updated review on treatment options. Current Oncology. 18: 173-179. PMID 21874107 DOI: 10.3747/Co.V18I4.738 |
0.507 |
|
| 2011 |
Yin S, Xu L, Bandyopadhyay S, Sethi S, Reddy KB. Cisplatin and TRAIL enhance breast cancer stem cell death. International Journal of Oncology. 39: 891-8. PMID 21687939 DOI: 10.3892/Ijo.2011.1085 |
0.536 |
|
| 2011 |
Xu L, Yin S, Banerjee S, Sarkar F, Reddy KB. Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. Molecular Cancer Therapeutics. 10: 550-7. PMID 21252285 DOI: 10.1158/1535-7163.Mct-10-0571 |
0.597 |
|
| 2011 |
Yin S, Xu L, Reddy K. P3-18-05: Triple-Negative Breast Cancer: Stem Cells, Cancer and New Treatment Strategy. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-18-05 |
0.601 |
|
| 2010 |
Yin S, Sethi S, Reddy KB. Protein kinase Cδ and caspase-3 modulate TRAIL-induced apoptosis in breast tumor cells. Journal of Cellular Biochemistry. 111: 979-87. PMID 20665667 DOI: 10.1002/Jcb.22786 |
0.476 |
|
| 2010 |
Kulkarni S, Reddy KB, Esteva FJ, Moore HC, Budd GT, Tubbs RR. Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene. 29: 1339-50. PMID 19946330 DOI: 10.1038/onc.2009.422 |
0.369 |
|
| 2007 |
Reddy KB, Glaros S. Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo. International Journal of Oncology. 30: 971-5. PMID 17332937 DOI: 10.3892/Ijo.30.4.971 |
0.618 |
|
| 2006 |
Glaros S, Atanaskova N, Zhao C, Skafar DF, Reddy KB. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Molecular Endocrinology (Baltimore, Md.). 20: 996-1008. PMID 16455819 DOI: 10.1210/Me.2005-0285 |
0.749 |
|
| 2005 |
Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K, Reddy KB. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene. 24: 3166-76. PMID 15735693 DOI: 10.1038/Sj.Onc.1208502 |
0.61 |
|
| 2004 |
Farhana L, Dawson MI, Huang Y, Zhang Y, Rishi AK, Reddy KB, Freeman RS, Fontana JA. Apoptosis signaling by the novel compound 3-Cl-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities. Oncogene. 23: 1874-84. PMID 14981538 DOI: 10.1038/Sj.Onc.1207311 |
0.568 |
|
| 2003 |
Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Molecular Cancer Research : McR. 1: 801-9. PMID 14517342 |
0.599 |
|
| 2003 |
Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Reviews. 22: 395-403. PMID 12884914 DOI: 10.1023/A:1023781114568 |
0.73 |
|
| 2002 |
Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene. 21: 4000-8. PMID 12037682 DOI: 10.1038/Sj.Onc.1205506 |
0.689 |
|
| 2002 |
Keshamouni VG, Mattingly RR, Reddy KB. Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. The Journal of Biological Chemistry. 277: 22558-65. PMID 11960991 DOI: 10.1074/Jbc.M202351200 |
0.616 |
|
| 2001 |
Reddy KB, McGowen R, Schuger L, Visscher D, Sheng S. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model. Oncogene. 20: 6538-43. PMID 11641778 DOI: 10.1038/Sj.Onc.1204796 |
0.41 |
|
| 2001 |
Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene. 20: 4209-18. PMID 11464287 DOI: 10.1038/Sj.Onc.1204541 |
0.692 |
|
| 1999 |
Reddy KB, Keshamouni VG, Chen YQ. The level of tyrosine kinase activity regulates the expression of p21/WAF1 in cancer cells. International Journal of Oncology. 15: 301-6. PMID 10402241 DOI: 10.3892/Ijo.15.2.301 |
0.528 |
|
| 1999 |
Reddy KB, Krueger JS, Kondapaka SB, Diglio CA. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. International Journal of Cancer. 82: 268-73. PMID 10389762 DOI: 10.1002/(Sici)1097-0215(19990719)82:2<268::Aid-Ijc18>3.0.Co;2-4 |
0.789 |
|
| 1998 |
Visscher DW, Sarkar FH, Kasunic TC, Reddy KB. Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia. Breast Cancer Research and Treatment. 45: 75-80. PMID 9285119 DOI: 10.1023/A:1005845512804 |
0.508 |
|
| 1997 |
Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. International Journal of Cancer. 70: 722-6. PMID 9096655 DOI: 10.1002/(Sici)1097-0215(19970317)70:6<722::Aid-Ijc15>3.0.Co;2-B |
0.603 |
|
| 1997 |
Visscher DW, Sarkar FH, Kusinic TC, Fridman R, Banerjee M, Reddy KB. Phospholipase C-? Immunostaining in Human Breast Carcinoma: Clinical Significance and Correlations with Protease and Growth-Factor Receptor Species The Breast Journal. 3: 350-356. DOI: 10.1111/J.1524-4741.1997.Tb00192.X |
0.611 |
|
| 1996 |
Kondapaka BS, Reddy KB. Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer. Molecular and Cellular Endocrinology. 117: 53-8. PMID 8734473 DOI: 10.1016/0303-7207(95)03725-X |
0.519 |
|
| Show low-probability matches. |